Iterum Therapeutics Files S-1/A Amendment

TL;DR

Iterum Therapeutics filed an S-1/A, updating its registration. Keep an eye on this.

AI Summary

Iterum Therapeutics plc filed an S-1/A amendment on July 17, 2024, related to its registration statement. The company, formerly known as Iterum Therapeutics Ltd, is incorporated in Ireland and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Dublin, Ireland, with a business phone number of +353 1 6694820.

Why It Matters

This filing indicates ongoing regulatory and financial activities for Iterum Therapeutics, which could impact its stock and future business operations.

Risk Assessment

Risk Level: low — This is a routine S-1/A filing, an amendment to a registration statement, which typically doesn't introduce new immediate risks.

Key Numbers

• 333-280045 — SEC File Number (Identifies the specific registration statement being amended.)
• 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• July 17, 2024 (date) — Filing Date
• Ireland (location) — Jurisdiction of Incorporation
• 2834 (other) — Standard Industrial Classification Code
• Iterum Therapeutics Ltd (company) — Former Company Name
• 20151124 (date) — Date of Name Change
• 333-280045 (other) — SEC File Number
• Corey N. Fishman (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $1.21 — 3,800 Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consi
• $0.01 — (i) our ordinary shares, nominal value $0.01 per share (the ordinary shares), and (i
• $0.605 — 0.50 Units, at a subscription price of $0.605 per 0.50 Units (the Subscription Price)
• $1.34 — ported on the Nasdaq Capital Market was $1.34 per share. There is no established publ
• $100,000 — e expenses of the dealer-manager, up to $100,000. See Plan of Distribution on page 70 of
• $250 million — non-affiliate public float in excess of $250 million and annual revenues in excess of $100 m
• $100 m — illion and annual revenues in excess of $100 million, or a non-affiliate public float
• $700 m — non-affiliate public float in excess of $700 million, each as determined on an annual

Filing Documents

• d821831ds1a.htm (S-1/A) — 646KB
• d821831dex11.htm (EX-1.1) — 154KB
• d821831dex415.htm (EX-4.15) — 78KB
• d821831dex416.htm (EX-4.16) — 76KB
• d821831dex417.htm (EX-4.17) — 90KB
• d821831dex418.htm (EX-4.18) — 91KB
• d821831dex419.htm (EX-4.19) — 35KB
• d821831dex51.htm (EX-5.1) — 20KB
• d821831dex52.htm (EX-5.2) — 30KB
• d821831dex231.htm (EX-23.1) — 3KB
• d821831dex991.htm (EX-99.1) — 33KB
• d821831dex992.htm (EX-99.2) — 16KB
• d821831dex993.htm (EX-99.3) — 17KB
• d821831dex994.htm (EX-99.4) — 15KB
• d821831dex995.htm (EX-99.5) — 6KB
• g821831dsp2.jpg (GRAPHIC) — 7KB
• g821831g0715113021258.jpg (GRAPHIC) — 2KB
• g821831g0716015247426.jpg (GRAPHIC) — 2KB
• g821831g0716015247606.jpg (GRAPHIC) — 2KB
• g821831g0717011012523.jpg (GRAPHIC) — 2KB
• g821831g21h43.jpg (GRAPHIC) — 3KB
• g821831g34m59.jpg (GRAPHIC) — 34KB
• 0001193125-24-180379.txt ( ) — 1379KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 24

USE OF PROCEEDS

USE OF PROCEEDS 26

DILUTION

DILUTION 27 DIVIDEND POLICY 28 THE RIGHTS OFFERING 29 DESCRIPTION OF UNITS 38 DESCRIPTION OF 1-YEAR WARRANTS 39 DESCRIPTION OF 5-YEAR WARRANTS 42 DESCRIPTION OF SHARE CAPITAL 45 MATERIAL TAX CONSIDERATIONS 61 PLAN OF DISTRIBUTION 72 LEGAL MATTERS 75 EXPERTS 75 WHERE YOU CAN FIND MORE INFORMATION 76 INCORPORATION BY REFERENCE 77 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the SEC). The exhibits to the registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase our securities, you should review the full text of these documents. The registration statement and the exhibits can be obtained from the SEC as indicated under the sections entitled Incorporation by Reference and Where You Can Find More Information. You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful, including under the sanctions laws and regulations of the European Union or the United States of America. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and

View Full Filing

View this S-1/A filing on SEC EDGAR